UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date
Industry Concerned Over Market Access As Five-Year Deal Reaches Half-Way Mark
Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.
You may also be interested in...
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.